CClinicalTrials.gg
TerminatedNCT04288180SAVRUpdated Oct 8, 2021

Social Anxiety Virtual Reality Study

An observational study in Social Anxiety Disorder, sponsored by Stanford University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-08.

Sponsored by Stanford University · Observational

Why this study was terminated
COVID-19 Pandemic
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
4
Ages
18 Years and older
Sex
All
01

Study summary

This project aims to validate a virtual reality paradigm that assesses maladaptive avoidance behavior in social anxiety disorder. It also aims to generate a significant scientific advance by testing the hypothesis that maladaptive avoidance maintains anxiety through disruptions in safety learning.

Read the detailed description

Although occasional mild social anxiety is a common human experience, social anxiety disorder has a devastating impact on patients' lives, leaving them vulnerable to medical, psychiatric, and socioeconomic complications. A key feature of social anxiety disorder is avoidance of social and/or performance situations in which judgment and evaluation from others might occur. Reducing avoidance is therefore an important treatment goal.

Despite the importance of avoidance, however, it is very difficult to assess a patient's tendency to avoid. Many prior assessments of avoidance measure adaptive (i.e., helpful) avoidance, in which an individual learns to avoid a truly noxious stimulus. However, anxiety disorders are characterized by maladaptive avoidance, in which a relatively safe stimulus is avoided resulting in interference with the individual's goals. In this study, the first aim is to validate a virtual reality paradigm to measure maladaptive avoidance behavior in adults with social anxiety disorder. The second aim is to test whether maladaptive avoidance behavior relates to safety learning (measured by a fear extinction task).

02

Conditions studied

  • Social Anxiety Disorder
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,388 are open to participants now.

This study's enrollment of 4 is below the median of 150 across 606 observational studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with primary social anxiety disorder, community sample

Inclusion criteria

  • age 18+
  • primary diagnosis of social anxiety disorder
  • fluent spoken and written English
  • able to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • history of manic episode, hypomanic episode, or psychosis
  • moderate or severe substance use disorder in the past 12 months
  • current major depressive episode greater than moderate severity (PHQ-9 score >14)
  • high risk for suicide (>8 on the MINI Suicidality section and/or clinician judgment that immediate medical attention is necessary)
  • general medical condition or impediment to vision, hearing, or motor function likely to interfere with assessments
  • benzodiazepine use in the past 2 weeks
  • cannabis use for anxiety management in the past 2 weeks
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
4 participants (actual)
Patient registry
No

Groups and cohorts

  • Social Anxiety Disorder

    A group of adults with social anxiety disorder will be recruited for a psychological/behavioral research study.

    Other: No intervention

Interventions

  • OtherNo intervention

    There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.

06

What researchers measure

Primary outcomes

  1. Maladaptive Avoidance Behavior

    Latency (in milliseconds) to enter the quadrant of the avoidance task containing the image from the fear learning task

    Time frame: Baseline

Secondary outcomes

  1. Maladaptive Avoidance Behavior (alternate measure)

    Amount of time (in milliseconds) spent in the quadrant of the avoidance task containing the image from the fear learning task

    Time frame: Baseline

  2. Maladaptive Avoidance Behavior (2nd alternate measure)

    Amount of time (in milliseconds) with center of gaze on the image from the fear learning task

    Time frame: Baseline

07

Study locations

1 site
  • Stanford University
    Palo Alto, California 94304, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04288180
Lead sponsor
Stanford University
Responsible party
Tali Manber Ball, PhD (Instructor, Stanford University) — Principal investigator
First posted
Feb 28, 2020
Start date
Jan 15, 2020
Primary completion
Feb 28, 2020
Completion
Feb 28, 2020
Last update
Oct 8, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion